Brian Abrahams

Leland Gershell

Dae Gon Ha

David Szeto

Elemer Piros

Kenny Chan

Kenny Shannon

Maurice Raycroft

Maury Raycroft

- The U.S. Food and Drug Administration (FDA) has granted **Fast Track designation** to Corbus Pharmaceuticals' **CRB-701** for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy.  **[1595097_0001193125-25-204389_crbp-ex99_1.htm:0]** **[1595097_0001193125-25-204389_crbp-20250916.htm:1]** **[1595097_0001193125-25-204389_crbp-20250916.htm:2]** 
- This is the **second Fast Track designation** for CRB-701, with the first granted in December 2024 for relapsed or refractory metastatic cervical cancer.  **[1595097_0001193125-25-204389_crbp-ex99_1.htm:0]** 
- Corbus Pharmaceuticals is scheduled to present **dose optimization data** from the Phase 1/2 study of CRB-701 at **ESMO 2025 on October 19, 2025**.  **[1595097_0001193125-25-204389_crbp-ex99_1.htm:0]**

Corbus Pharmaceuticals Receives FDA Fast Track Designation for CRB-701 in HNSCC

Corbus Pharmaceuticals Holdings (CRBP)